» Articles » PMID: 30976792

Foxr2 Promotes Formation of CNS-embryonal Tumors in a Trp53-deficient Background

Overview
Journal Neuro Oncol
Specialties Neurology
Oncology
Date 2019 Apr 13
PMID 30976792
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Embryonal tumors in the central nervous system (CNS) are primary, aggressive, and poorly differentiated pediatric brain tumors. We identified forkhead box R2 (Foxr2) as an oncogene for medulloblastoma through a transposon-based insertional mutagenesis screen. Foxr2 translocation has been identified in a subset of human embryonal tumors of the CNS, designated as CNS neuroblastoma with Foxr2 activation (CNS NB-Foxr2); however, the in vivo functions of Foxr2 remain elusive.

Methods: We analyzed the effect of Foxr2 overexpression in the mouse brain by generating a transgenic strain that expresses Foxr2 in the entire brain under a transformation related protein 53 (Trp53)-deficient background. We performed histological analysis of tumors and characterized tumor-derived sphere-forming cells. We investigated gene expression profiles of tumor-derived cells.

Results: Foxr2 and Trp53 loss promoted tumor formation in the olfactory bulb (OB) and brainstem (BS). The tumors showed the common morphological features of small round blue cell tumors, exhibiting divergent, mainly neuronal and glial, patterns of differentiation, which corresponds to the definition of CNS-embryonal tumors. Importantly, all mice developed CNS-embryonal tumors. In the OB, early proliferative lesions consisting of oligodendrocyte transcription factor 2 (Olig2+) cells were observed, indicating that Foxr2 expression expanded Olig2+ cells in the OB. Tumor-derived cells formed spheres in vitro and induced tumors that recapitulated the parental tumor upon transplantation, indicating the presence of tumor-initiating cells. Gene expression profiling revealed that OB and BS tumor cells were enriched for the expression of the genes specific to CNS NB-Foxr2.

Conclusion: Our data demonstrate that Foxr2 plays a causative role in the formation of CNS-embryonal tumors.

Citing Articles

Recent Advances in Pineoblastoma Research: Molecular Classification, Modelling and Targetable Vulnerabilities.

Jiang Z, Allkanjari M, Chung P, Tran H, Ghanbari-Azarnier R, Wang D Cancers (Basel). 2025; 17(5).

PMID: 40075567 PMC: 11898778. DOI: 10.3390/cancers17050720.


FOXR2 in cancer development: emerging player and therapeutic opportunities.

Yang P, Sheykhhasan M, Heidari R, Chamanara M, Dama P, Ahmadieh-Yazdi A Oncol Res. 2025; 33(2):283-300.

PMID: 39866234 PMC: 11753994. DOI: 10.32604/or.2024.052939.


FOXR2 Targets LHX6+/DLX+ Neural Lineages to Drive Central Nervous System Neuroblastoma.

Jessa S, De Cola A, Chandarana B, McNicholas M, Hebert S, Ptack A Cancer Res. 2024; 85(2):231-250.

PMID: 39495206 PMC: 11733536. DOI: 10.1158/0008-5472.CAN-24-2248.


A human embryonic stem cell-based model reveals the cell of origin of FOXR2-activated CNS neuroblastoma.

Royston H, Hampton A, Bhagat D, Pinto E, Emerson M, Funato K Neurooncol Adv. 2024; 6(1):vdae144.

PMID: 39220247 PMC: 11364937. DOI: 10.1093/noajnl/vdae144.


A genetic basis for sex differences in Xp11 translocation renal cell carcinoma.

Achom M, Sadagopan A, Bao C, McBride F, Li J, Konda P Cell. 2024; 187(20):5735-5752.e25.

PMID: 39168126 PMC: 11455617. DOI: 10.1016/j.cell.2024.07.038.